What is a stock summary page? Click here for an overview.
Business Description
Medexus Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA70533E1088
Compare
Compare
Traded in other countries / regions
MDP.CanadaMEDXF.USAP731.Germany IPO Date
2017-11-02Description
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 1.21 | |||||
| Debt-to-EBITDA | 2.32 | |||||
| Interest Coverage | 1.79 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.7 | |||||
| Beneish M-Score | -3.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.1 | |||||
| 3-Year EPS without NRI Growth Rate | 58.5 | |||||
| 3-Year Book Growth Rate | 12.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 3.35 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.14 | |||||
| 9-Day RSI | 33.24 | |||||
| 14-Day RSI | 35.81 | |||||
| 3-1 Month Momentum % | 6.84 | |||||
| 6-1 Month Momentum % | 8.5 | |||||
| 12-1 Month Momentum % | 88.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.01 | |||||
| Quick Ratio | 0.49 | |||||
| Cash Ratio | 0.13 | |||||
| Days Inventory | 232.24 | |||||
| Days Sales Outstanding | 57.14 | |||||
| Days Payable | 227.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 | |||||
| Shareholder Yield % | 34.28 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.43 | |||||
| Operating Margin % | 13.72 | |||||
| Net Margin % | 3.25 | |||||
| FCF Margin % | 18.69 | |||||
| ROE % | 11.31 | |||||
| ROA % | 2.38 | |||||
| ROIC % | 16.52 | |||||
| 3-Year ROIIC % | -286.32 | |||||
| ROC (Joel Greenblatt) % | 83.09 | |||||
| ROCE % | 13.49 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.49 | |||||
| Forward PE Ratio | 16.33 | |||||
| PE Ratio without NRI | 6.44 | |||||
| Price-to-Owner-Earnings | 5.08 | |||||
| PS Ratio | 0.42 | |||||
| PB Ratio | 1.33 | |||||
| Price-to-Free-Cash-Flow | 2.23 | |||||
| Price-to-Operating-Cash-Flow | 1.96 | |||||
| EV-to-EBIT | 7.69 | |||||
| EV-to-EBITDA | 5.01 | |||||
| EV-to-Forward-EBITDA | 9.14 | |||||
| EV-to-Revenue | 0.81 | |||||
| EV-to-Forward-Revenue | 0.88 | |||||
| EV-to-FCF | 4.52 | |||||
| Price-to-GF-Value | 1.2 | |||||
| Price-to-Projected-FCF | 0.77 | |||||
| Price-to-Median-PS-Value | 0.39 | |||||
| Earnings Yield (Greenblatt) % | 13 | |||||
| FCF Yield % | 35.87 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers